BioSpace News Archive

Healthcare Integrated Technologies, Inc. (“HITC”) is excited to announce the expansion of its strategic partnership with Merrill Gardens Senior Living. HITC will install its innovative SafeSpace™ with AI Vision™ fall detection technology in a second of Merrill Gardens’ seventy-two communities.

CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology platform company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of results from the Company’s completed randomized, open-label, dose-response Phase 2a study in the peer-reviewed journal Pancreas

The conference will be held virtually on June 17, 2021.

LifeQ, the preeminent independent provider of biometrics and health information derived from wearable devices and used in world-leading health management solutions, announced it has partnered with South Africa-based insurance leader 1Life on a new version of its COVID-19 screening application.

A new Health Union survey reveals people with myasthenia gravis who see a healthcare professional trained in the condition have more favorable treatment-related perspectives, knowledge about their condition and community support than those who don’t see a relevant specialist.

New research published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes) shows clinically meaningful reductions in Hemoglobin A1c (HbA1c) levels for participants enrolled in Vida Health’s virtual diabetes management program.

The report highlights trends prevailing in the market, and the factors driving and hindering the market growth.

Today, the U.S. Food and Drug Administration authorized marketing of a device to help diagnose autism spectrum disorder (ASD).

Mymee announced today that it will be presenting two abstracts at the upcoming Institute for Functional Medicine’s online Annual International Conference (AIC) from June 3 – 5, 2021.

Humanetics Corporation (Humanetics) announced today that it has received a business development grant from Regenerative Medicine Minnesota to conduct a series of nonclinical studies with its investigational drug, BIO 300.